Work

AAV encoding miRNAs as a new therapeutic for choroidal neovascularization

Year: 2026

Type: article

Abstract: Better treatments are urgently needed for eye conditions when existing therapies fall short. Age-related macular degeneration (AMD) is a significant contributor to irreversible central vision impairment in an aging population. The neovascular form of AMD (nAMD) accounts for most severe vision loss due to choroidal neovascularization (CNV), a process often leading to subretinal hemorrhage, photoreceptor cell death, and ultimately permanent fibrovascular scarring.1 At present, standard treatments use recombinant anti-VEGF fusion proteins or antibodies injected intravitreally every few months.

Source: Molecular Therapy — Nucleic Acids

DOI: 10.1016/j.omtn.2026.103135

Authors: Marc-Antoine Turcotte, Carole Dinant, Ian M. MacDonald

Institutions: Centre Hospitalier Universitaire Sainte-Justine, CHU Sainte-Justine Research Center, Université de Montréal

Language: English

Topic: Retinal Diseases and Treatments

Subfield: Ophthalmology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900